• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Restenosis begets restenosis: implications for stent selection.再狭窄导致再狭窄:对支架选择的影响。
Neth Heart J. 2008 Nov;16(11):376-81. doi: 10.1007/BF03086182.
2
Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.血管内超声引导经皮冠状动脉介入治疗:一项基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(12):1-97. Epub 2006 Apr 1.
3
4
The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.血管成像在常规经皮冠状动脉介入治疗中的作用:金属裸支架和药物洗脱支架试验的荟萃分析。
Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160.
5
Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience.药物洗脱支架植入术后左主干远端/分叉处再狭窄的管理:单中心经验
Cardiovasc Revasc Med. 2014 Mar;15(2):76-9. doi: 10.1016/j.carrev.2014.01.008. Epub 2014 Jan 20.
6
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.冠状动脉血运重建术后卒率比较:外科手术与经皮冠状动脉介入治疗。
J Am Coll Cardiol. 2018 Jul 24;72(4):386-398. doi: 10.1016/j.jacc.2018.04.071.
7
Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.对接受药物洗脱支架植入的经皮冠状动脉介入治疗的冠心病患者快速血管造影狭窄进展和再狭窄风险的预测因素进行综合分析。
J Clin Lab Anal. 2019 Feb;33(2):e22666. doi: 10.1002/jcla.22666. Epub 2018 Sep 17.
8
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.紫杉醇洗脱支架与血管内近距离放射治疗用于裸金属支架内支架再狭窄的比较:TAXUS V ISR随机试验
JAMA. 2006 Mar 15;295(11):1253-63. doi: 10.1001/jama.295.11.1253. Epub 2006 Mar 12.
9
Drug-Coated Balloon Angioplasty for De Novo Lesions on the Left Anterior Descending Artery.药物涂层球囊血管成形术治疗左前降支新发病变。
Circ Cardiovasc Interv. 2023 Dec;16(12):e013232. doi: 10.1161/CIRCINTERVENTIONS.123.013232. Epub 2023 Oct 24.
10
Intracoronary Stents冠状动脉内支架

本文引用的文献

1
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.西罗莫司洗脱支架和紫杉醇洗脱支架在常规临床实践中的早期和晚期冠状动脉支架血栓形成:来自一项大型双机构队列研究的数据。
Lancet. 2007 Feb 24;369(9562):667-78. doi: 10.1016/S0140-6736(07)60314-6.
2
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.西罗莫司和紫杉醇洗脱冠状动脉支架的安全性与有效性
N Engl J Med. 2007 Mar 8;356(10):998-1008. doi: 10.1056/NEJMoa067193. Epub 2007 Feb 12.
3
Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.药物洗脱支架的晚期血栓形成:随机临床试验的荟萃分析
Am J Med. 2006 Dec;119(12):1056-61. doi: 10.1016/j.amjmed.2006.01.023.
4
Outcome of patients with prior percutaneous revascularization undergoing repeat coronary intervention (from the PRESTO Trial).曾接受经皮血管重建术的患者再次进行冠状动脉介入治疗的结果(来自PRESTO试验)
Am J Cardiol. 2005 Sep 15;96(6):741-6. doi: 10.1016/j.amjcard.2005.05.013.
5
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.脂蛋白脂肪酶基因多态性与经皮冠状动脉介入治疗后靶血管血运重建风险
J Am Coll Cardiol. 2005 Sep 20;46(6):1093-100. doi: 10.1016/j.jacc.2005.05.071.
6
Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).在真实临床环境中药物洗脱支架与第三代裸金属支架相比的增量成本效益:随机巴塞尔支架成本效益试验(BASKET)
Lancet. 2005;366(9489):921-9. doi: 10.1016/S0140-6736(05)67221-2.
7
One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.雷帕霉素洗脱支架与裸金属支架治疗单处原发性冠状动脉新发病变的一年成本效益:来自RAVEL试验的分析
Heart. 2005 Apr;91(4):507-12. doi: 10.1136/hrt.2004.034454.
8
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.经皮冠状动脉介入治疗指南。欧洲心脏病学会经皮冠状动脉介入治疗特别工作组。
Eur Heart J. 2005 Apr;26(8):804-47. doi: 10.1093/eurheartj/ehi138. Epub 2005 Mar 15.
9
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement.
Thromb Haemost. 2005 Mar;93(3):564-9. doi: 10.1160/TH04-11-0708.
10
Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
J Am Coll Cardiol. 2005 Jan 18;45(2):198-203. doi: 10.1016/j.jacc.2004.05.089.

再狭窄导致再狭窄:对支架选择的影响。

Restenosis begets restenosis: implications for stent selection.

机构信息

Department of Cardiology, Thoraxcenter, University Medical Center Groningen, the Netherlands.

出版信息

Neth Heart J. 2008 Nov;16(11):376-81. doi: 10.1007/BF03086182.

DOI:10.1007/BF03086182
PMID:19065276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2584766/
Abstract

BACKGROUND

Identifying the risk for restenosis is of critical importance in the stent selection process of patients undergoing percutaneous coronary intervention (PCI). Therefore, we sought to determine if a history of clinical recurrence (CR) after PCI increases the risk of CR after treatment of a de novo lesion in another coronary artery.

METHODS

We retrospectively analysed all 12,763 patients who underwent PCI between 1993 and 2004 and selected patients with two or more interventions in two different native vessels. These patients were divided into two groups: patients without CR, and patients with CR after the first PCI. Clinical recurrence was defined as revascular-isation of the target vessel by either PCI or CABG within one year.

RESULTS

A total of 1010 patients with two or more interventions in two different native vessels were identified: 727 patients without and 283 patients with CR after the first PCI. Baseline patient characteristics and conventional risk factors were comparable between the two groups. Patients with a history of CR had a higher risk of CR after a second intervention in a second vessel (OR=3.4, 95% CI=2.3 to 4.9). A total of 112 patients also had a third intervention in a third native vessel: 12 patients with two CR, 30 patients with one CR and 70 patients with no CR after the first two interventions. CR rates in these patients were 50, 17 and 3%, respectively (p<0.001).

CONCLUSION

Patients with a history of CR have a markedly increased risk of developing CR after a second or third PCI in a different coronary artery. Therefore, in the decision-making process on whether to use a bare metal stent or drug-eluting stent, the history of CR is a simple and powerful aid. (Neth Heart J 2008;16:376-81.).

摘要

背景

在经皮冠状动脉介入治疗(PCI)中,确定再狭窄的风险至关重要。因此,我们试图确定 PCI 后临床复发(CR)的病史是否会增加另一支冠状动脉新发病变治疗后 CR 的风险。

方法

我们回顾性分析了 1993 年至 2004 年间接受 PCI 的 12763 例患者,并选择了在两个不同的原生血管中有两次或更多次介入的患者。这些患者分为两组:无 CR 组和首次 PCI 后有 CR 组。临床复发定义为在一年内通过 PCI 或 CABG 对靶血管进行血运重建。

结果

共确定了 1010 例在两个不同原生血管中有两次或更多次介入的患者:727 例无 CR,283 例首次 PCI 后有 CR。两组患者的基线特征和传统危险因素相似。有 CR 病史的患者在第二次介入时发生第二次血管 CR 的风险更高(OR=3.4,95%CI=2.3 至 4.9)。共有 112 例患者还在第三个原生血管中进行了第三次介入:12 例有两次 CR,30 例有一次 CR,70 例在前两次介入后无 CR。这些患者的 CR 发生率分别为 50%、17%和 3%(p<0.001)。

结论

有 CR 病史的患者在不同冠状动脉中进行第二次或第三次 PCI 后发生 CR 的风险明显增加。因此,在决定是否使用金属裸支架或药物洗脱支架时,CR 病史是一个简单而有力的辅助手段。(荷兰心脏杂志 2008;16:376-81.)。